Abstract: Objective The aim of this study was to observe the efficacy of telbivudine on viral load loss and mother-to-child transmission in pregnant women with chronic hepatitis B viral carrier. Methods 60 pregnant women with HBV carrier were randomly divided into two groups in our hospital between February 2016 and February 2018, and 30 cases in the observation at six month of pregnancy were, while another 30 in the control were not given telbivudine until the end of delivery. All newborns were routinely injected with recombinant hepatitis B vaccine and hepatitis B immunoglobulin after birth. Serum HBV DNA, HBsAg, interleukin-2 (IL-2), IL-4 and IL-6 levels were assayed. Results Before anti-viral treatment, serum HBV DNA loads in the two groups were not significantly different (P>0.05), while serum HBV DNA level after delivery in the observation group was (3.7±0.7)lg copies/mL, significantly lower than 【(7.8±1.0)lg copies/mL, P<0.05】 in the control; after delivery, serum IL-2 level in the anti-viral group was (20.6±2.7)pg/mL, significantly higher than 【(15.7±1.3)pg/mL, P<0.05】, serum IL-4 level was (19.7±1.5)pg/mL, significantly lower than 【(30.6±2.8)pg/mL, P<0.05】, and serum IL-6 level was (21.5±4.2)pg/mL, much lower than 【(29.7±5.1)pg/mL, P<0.05】 in the control; the gestational age, height, body mass and Apgar’s scores of newborns in the two groups were not significantly different (P>0.05); at 6 month and one year follow-up, there was one infant having HBV infection in the control, while there was no infant infected in the observation. Conclusion We recommend oral telbivudine administration at second trimester of pregnancy for blocking mother-to-child HBV transmission in women carrying HBV, which might safe and efficacious.

Key words: Hepatitis B viral carrier, Telbivudine, Mother-to-child transmission, Newborns, Pregnancy